APHON and its community provide a variety of events to help you keep pace with advancements in pediatric hematology/oncology nursing. You can view APHON events, local chapter events, Pediatric Chemotherapy/Biotherapy Provider courses, industry events, upcoming webinars, or the calendar of all events. The calendar name will indicate which events you are viewing.
Immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a promising modality of treatment for patients with relapsed or refractory (R/R) malignancy. CAR T cells are patient derived T cells that are genetically modified ex vivo, using a retroviral vector, to specifically target cancer antigens on the surface of malignant cells. Most notable is the successful clinical application for patients with R/R B cell acute lymphoblastic leukemia (B-ALL) when targeting the B cell antigen CD19 . Key to the successful application of CAR T cells immunotherapy is (i) identifying patients with appropriate target antigen expression, (ii) coordinating T cell collection to maximize T cell yield, (iii) developing standardized procedures for infusion of CAR T cells, and (iv) managing/preventing toxicities following CAR T cell infusion.
As the use of targeted therapy with tumor specific T cells becomes more prevalent, it is essential that the nursing staff stay abreast of these current therapies. This lecture aims to enhance the pediatric oncology nurse’s knowledge on the uses, risks and management of CAR T cell therapy.
APHON would like to thank our educational grantor Novartis for their support.
Disclaimer: APHON does not participate in the planning or execution of the provider course or any local chapter activity, and does not endorse any material produced by local chapters.